News
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Tharimmune partners with Intract Pharma to license oral anti-TNF-α antibody for autoimmune diseases. The innovative delivery platform aims to enhance treatment effectiveness and patient compliance -